CRVS - Corvus Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
4.1200
-0.0200 (-0.48%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close4.0400
Open4.0600
Bid3.58 x 800
Ask4.43 x 3100
Day's Range4.0200 - 4.1900
52 Week Range3.2200 - 13.9100
Volume51,016
Avg. Volume106,867
Market Cap120.642M
Beta (3Y Monthly)0.85
PE Ratio (TTM)N/A
EPS (TTM)-1.91
Earnings DateAug 3, 2017 - Aug 7, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est17.00
Trade prices are not sourced from all markets
  • GlobeNewswire11 days ago

    Corvus Announces Presentation of Preclinical Data on CPI-818, a First-in-class Covalent Inhibitor of ITK Targeting T-Cell Lymphomas

    Study results indicated that orally-administered CPI-818 produced tumor regression in three of three companion dogs with spontaneous, naturally occurring T-cell lymphomas, without significant toxicity. Based on these data, Corvus plans to submit an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) in early 2019.

  • GlobeNewswire13 days ago

    Corvus Announces Enrollment in Second Arm of Phase 1/1b Dose-Escalation Trial of Anti-CD73 Antibody, CPI-006, Focused on Combination with CPI-444 Adenosine Antagonist

    Corvus Pharmaceuticals, Inc. (CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced that it has initiated patient enrollment in the second arm of its ongoing Phase 1/1b dose-escalation study. This arm is evaluating CPI-006, a humanized monoclonal antibody directed against CD73, in combination with CPI-444, a selective and potent inhibitor of the adenosine A2A receptor. The Phase 1/1b study is currently enrolling patients with non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC) and other cancers who have failed standard therapies.  The first arm of the study is evaluating CPI-006 as a single agent and has dosed patients in several cohorts of escalating doses.

  • Ziopharm Oncology (ZIOP) in Focus: Stock Moves 6.2% Higher
    Zacks24 days ago

    Ziopharm Oncology (ZIOP) in Focus: Stock Moves 6.2% Higher

    Ziopharm Oncology (ZIOP) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

  • Sarepta Stock More Than Doubles This Year So Far: Here's Why
    Zacks2 months ago

    Sarepta Stock More Than Doubles This Year So Far: Here's Why

    Sarepta's (SRPT) key product, Exondys 51, continues to perform well. Its lead pipeline candidate, golodirsen, is also making good progress. The company is also developing gene therapies.

  • GlobeNewswire2 months ago

    Corvus Pharmaceuticals to Present at the 27th Annual Credit Suisse Healthcare Conference

    BURLINGAME, Calif., Nov. 12, 2018 -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of.

  • GlobeNewswire2 months ago

    Corvus Pharmaceuticals Announces Updated Results from Ongoing Clinical Studies of Lead Programs, CPI-444 and CPI-006, at SITC 33rd Annual Meeting

    Corvus Pharmaceuticals, Inc. (CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced updated clinical and biomarker data from ongoing Phase 1/1b studies of its lead programs, CPI-444 and CPI-006. Updated results from its Phase 1/1b clinical trial of CPI-444 in patients with treatment-refractory renal cell carcinoma (RCC) demonstrated an overall survival (OS) of 88 percent at more than 20 months follow-up with CPI-444 administered in combination with atezolizumab. The clinical data were presented in an oral session at the Society for Immunotherapy of Cancer's (SITC) 33rd Annual Meeting in Washington, D.C., by Lawrence Fong, M.D., study investigator and leader of the Cancer Immunotherapy Program at the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center.

  • GlobeNewswire2 months ago

    Corvus Pharmaceuticals to Webcast Investor & Analyst Event on November 10, 2018

    Event will provide a review of new CPI-444 and CPI-006 data presented at SITC & ESMO BURLINGAME, Calif., Nov. 05, 2018 -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a.

  • Associated Press3 months ago

    Corvus: 3Q Earnings Snapshot

    The Burlingame, California-based company said it had a loss of 36 cents per share. Corvus shares have dropped 21 percent since the beginning of the year. The stock has declined 41 percent in the last 12 ...

  • GlobeNewswire3 months ago

    Corvus Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update

    Corvus Pharmaceuticals, Inc. (CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced financial results for the third quarter ended September 30, 2018, and provided a business update. “We continue to make significant progress in the clinic both with CPI-444 and with CPI-006,” said Richard A. Miller, M.D., co-founder, president and chief executive officer of Corvus. This includes biomarker data for CPI-444 that our team presented at the ESMO 2018 Congress on October 22, 2018.

  • Corvus Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?
    Zacks4 months ago

    Corvus Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?

    Corvus Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?

  • Associated Press6 months ago

    Corvus: 2Q Earnings Snapshot

    On a per-share basis, the Burlingame, California-based company said it had a loss of 40 cents. Corvus shares have fallen 9 percent since the beginning of the year. In the final minutes of trading on Thursday, ...

  • ACCESSWIRE10 months ago

    Blog Exposure - Checkpoint Therapeutics to Present Preclinical Data on its BET Inhibitor CK-103 at AACR Meeting

    Stock Monitor: Corvus Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 19, 2018 / Active-Investors.com has just released a free research report on Checkpoint Therapeutics, Inc. (NASDAQ: CKPT ...